Antithymocyte globulin, rabbit ATG (Grafalon)

Note: this formulation of ATG is not FDA-approved in the United States, but is commonly used in Europe, the Middle East, and Asia.

General information

Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Aplastic anemia
• Myelodysplastic syndrome
• Transplant conditioning regimens

Also known as

ATG-Fresenius, Anti-thymocyte globulin, antithymocyte globulin (rabbit), lymphocyte immune globulin.